EP3528848A4 - Schutzwirkung von dmpc, dmpg, dmpc/dmpg, egpg, lysopg und lysopc gegen arzneimittel, die kanalopathien hervorrufen - Google Patents

Schutzwirkung von dmpc, dmpg, dmpc/dmpg, egpg, lysopg und lysopc gegen arzneimittel, die kanalopathien hervorrufen Download PDF

Info

Publication number
EP3528848A4
EP3528848A4 EP17861307.1A EP17861307A EP3528848A4 EP 3528848 A4 EP3528848 A4 EP 3528848A4 EP 17861307 A EP17861307 A EP 17861307A EP 3528848 A4 EP3528848 A4 EP 3528848A4
Authority
EP
European Patent Office
Prior art keywords
dmpg
dmpc
egpg
lysopg
protective effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17861307.1A
Other languages
English (en)
French (fr)
Other versions
EP3528848A1 (de
Inventor
Lawrence Helson
George M. SHOPP
Annie Bouchard
Muhammed Majeed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signpath Pharma Inc
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/297,901 external-priority patent/US10449193B2/en
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of EP3528848A1 publication Critical patent/EP3528848A1/de
Publication of EP3528848A4 publication Critical patent/EP3528848A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP17861307.1A 2016-10-19 2017-10-19 Schutzwirkung von dmpc, dmpg, dmpc/dmpg, egpg, lysopg und lysopc gegen arzneimittel, die kanalopathien hervorrufen Withdrawn EP3528848A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/297,901 US10449193B2 (en) 2011-06-03 2016-10-19 Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
PCT/US2017/057446 WO2018075801A1 (en) 2016-10-19 2017-10-19 Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Publications (2)

Publication Number Publication Date
EP3528848A1 EP3528848A1 (de) 2019-08-28
EP3528848A4 true EP3528848A4 (de) 2020-07-15

Family

ID=62019674

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17861307.1A Withdrawn EP3528848A4 (de) 2016-10-19 2017-10-19 Schutzwirkung von dmpc, dmpg, dmpc/dmpg, egpg, lysopg und lysopc gegen arzneimittel, die kanalopathien hervorrufen

Country Status (8)

Country Link
EP (1) EP3528848A4 (de)
JP (1) JP2019531309A (de)
KR (1) KR20190042775A (de)
CN (2) CN111481508A (de)
AU (2) AU2017345473A1 (de)
CA (1) CA3039596C (de)
MX (1) MX2019004222A (de)
WO (1) WO2018075801A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3697386B1 (de) * 2017-10-19 2023-07-26 Signpath Pharma, Inc. Flüssige zusammensetzungen zur peroralen verwendung umfassend phosphatidylglycerol derivate und thixotropische hilfsstoffe zur behandlung von herzkanalopathien verursacht durch pharmakologische wirkstoffe

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120308643A1 (en) * 2011-06-03 2012-12-06 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
US20150343063A1 (en) * 2014-06-03 2015-12-03 Signpath Pharma Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20050233970A1 (en) * 2004-03-23 2005-10-20 Praecis Pharmaceuticals, Inc. Methods for treating long QT syndrome
JPWO2008093848A1 (ja) * 2007-02-02 2010-05-20 サンスター株式会社 ホスファチジルコリンを含有する炎症マーカー低減組成物
JP5638204B2 (ja) * 2009-05-29 2014-12-10 国立大学法人 岡山大学 経口投与用リポソーム製剤およびその製造方法
WO2012094033A1 (en) * 2011-01-05 2012-07-12 Livon Laboratories Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
EP2814497A4 (de) * 2012-02-16 2015-12-09 Vascular Biogenics Ltd Verfahren zur behandlung von psoriasis und gefässentzündung
AT515178A5 (de) * 2012-08-31 2015-07-15 Univ North Texas Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120308643A1 (en) * 2011-06-03 2012-12-06 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
US20150343063A1 (en) * 2014-06-03 2015-12-03 Signpath Pharma Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018075801A1 *

Also Published As

Publication number Publication date
AU2017345473A1 (en) 2019-04-18
MX2019004222A (es) 2019-06-10
AU2020267307A1 (en) 2020-12-10
CN109843331A (zh) 2019-06-04
WO2018075801A1 (en) 2018-04-26
JP2019531309A (ja) 2019-10-31
CA3039596C (en) 2022-04-12
KR20190042775A (ko) 2019-04-24
CA3039596A1 (en) 2018-04-26
EP3528848A1 (de) 2019-08-28
CN111481508A (zh) 2020-08-04

Similar Documents

Publication Publication Date Title
EP3151837A4 (de) Schutzwirkung von dmpc, dmpg, dmpc/dmpg, egpg, lysopg und lysopc gegen arzneimittel, die kanalopathien hervorrufen
EP3538106A4 (de) Schutzwirkung von dmpc, dmpg, dmpc/dmpg, lysopg und lysopc gegen arzneimittel, die kanalopathien hervorrufen
EP3442706A4 (de) Probensammel- und konservierungsvorrichtungen, systeme und verfahren
EP3210364B8 (de) Systeme und verfahren zur anwendungssicherheitsanalyse
EP3463248A4 (de) Vorrichtungen und verfahren zur verwendung von medikamentenvorrichtungen
EP3320347A4 (de) Systeme, verfahren und vorrichtungen zur selbstdigitalisierung von proben
EP3197518A4 (de) Arzneimittelzubereitung sowie behandlungsvorrichtungen, -verfahren und -systeme
EP3551835A4 (de) Bohrkopfsysteme und -verfahren
EP3265217A4 (de) Trommelsysteme und -verfahren
EP3420456B8 (de) Wiedergabeschutzsysteme und verfahren
EP3125970A4 (de) Medizinischer zugangsport, systeme und verfahren zur verwendung davon
EP3405634A4 (de) Türhaltevorrichtung und sicherheitssystem
EP3400050A4 (de) Wirkstofffreisetzungsvorrichtung und verwendung
EP3150634A4 (de) Anti-muc1-antikörper oder antigenbindendes fragment davon und verwendung davon
EP3442567A4 (de) Anti-psma-antikörper und verwendung davon
EP3510986A4 (de) Mobilitätsvorrichtung und mobilitätssystem
EP3110352A4 (de) Wirbelsäulen-cage, system und montageverfahren sowie verwendung
EP3209766A4 (de) Gewebeprobeverarbeitungssystem und zugehörige verfahren
EP3100683A4 (de) Vorrichtung zur verarbeitung photoakustischer signale, system zur verarbeitung photoakustischer signale und verfahren zur verarbeitung photoakustischer signale
EP3435665A4 (de) Überwachungsvorrichtung und überwachungssystem
EP3488431A4 (de) Sicherheitsüberwachungssystem und -verfahren
EP3509413A4 (de) Systeme und verfahren zur gewinnung von medizinischem cannabis
EP3136948A4 (de) Systeme und verfahren für nicht-intrusive arzneimittelstörungserkennung
EP3483873A4 (de) Rauschverringerungsvorrichtung und rauschverringerungssystem
EP3419267A4 (de) Notfallbenachrichtigungsvorrichtung und notfallbenachrichtigungssystem

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190402

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200615

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20200608BHEP

Ipc: A61K 47/24 20060101AFI20200608BHEP

Ipc: A61K 9/127 20060101ALI20200608BHEP

Ipc: A61K 31/506 20060101ALI20200608BHEP

Ipc: A61P 9/00 20060101ALI20200608BHEP

Ipc: A61K 31/683 20060101ALI20200608BHEP

Ipc: A61K 31/685 20060101ALI20200608BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220609

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221020